Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded
MGA’s Alex Brill submitted a letter in response to a request for information from the Federal Trade Commission. The FTC was looking for information regarding the business practices of pharmacy benefit managers (PBMs) and their impact on pharmacies and consumers. Brill’s letter detailed his findings from earlier this year. These findings showed that PBM rebates do not cause an increase in drug prices. In fact, PBMs are vital to keep pricing competitive among insurance companies and drug manufacturers.
Read the letter here.
Read here for more information about the Coalition for Affordable Prescription Drugs working with MGA on the report.
